PARTNER TODAY

Leveraging our expertise in chemical development, INTEROR has crafted an extensive array of in-house Intermediates, catering to both international valued client requirements and our own portfolio (variety substituted pyridines, piperidines, chloroalkylamines, quinuclidines, brominated compounds).

Reliable partner in fine chemicals : advanced organic intermediates CDMO - CRO


3 CORE INDUSTRIES

Pharmaceutical
Industry

Specialty
Chemicals

Cosmetics

SPECIALIST
OF COMPLEX
CHEMICAL PROCESS

  • Catalytic hydrogenations
  • (very high pressure and high temperature)
  • Grignard reactions
  • Brominations with liquid Br2
  • Chlorinations…

PRODUCER
OF OUR OWN CATALOG

  • Quinuclidines
  • Brominated compounds
  • Variety substituted pyridines
  • Piperidines
  • Chloroalkylamines 
     

PARTNER FOR THE FUTURE

DRIVEN BY RESEARCH

 

  • Research and development services (6% of the Turn Over)
  • Small molecules analytical laboratories
  • Manufacturing capacities from investigational to commercial-scale development programs

substances.png

QUALITY DRUG SUBSTANCES

LEADER in method development, method validation, method transfer, and application of analytical, expertise
 

operationnal.png

OPERATIONAL EXCELLENCE

World-class facilities
Safety, quality, delivery, cost, compliance
 

sustainability.png

SUSTAINABILITY
FOR A BETTER WORLD

Energy, water, waste management,
CSR & governance

Technologies
Catalog

Interor history

1975

Creation of the company by Mr. & Mrs. Michel Ratti

1976-1984

Construction of the 1st industrial buildings, the R&D laboratory and the QC Lab

1988

Construction of a new production building and its annexes

1998 - 2000

Major investment programme (6 storage units, distillation unit, fire safety, treatment plant ...)
Turn over > 20 M€

2017 - 2018

  • Construction of 2 drying rooms (ISO8 cleanroom with HVAC)
  • QC Lab renovation & modernization with data integrity equipment
  • Securement of the Grignard Unit (5 reactors)
  • Turn over > 33 M€

2020 : towards a new horizon

December 16, 2020 : Turenne Groupe acquires Interor
Turenne Santé and management continue the growth of the company, the modernization of facilities and support customers in their projects.

Key figures

  • 145 employees
  • 160m3smalls molecules
    manufacturing capacity
  • 5 buildings6th under construction
    cGMP
  • 40 reactors1500 L to 8000 L
  • Since 1976

We guarantee our clients a completely independent, close and trusted partnership.

Contact us